Marketdash
Back to News

Analyst Loses Faith in Argenx: 5 Notable Downgrades to Start the Week

MarketDash Editorial Team
14 days ago
Wall Street analysts pulled back their bullish stances on several stocks Monday, with Argenx taking the biggest hit as Wolfe Research shifted from Outperform to Peer Perform. Other downgrades hit energy, battery tech, healthcare, and real estate sectors.

Some Wall Street analysts are having second thoughts. Monday brought a wave of downgrades across sectors, with biotechnology, energy partnerships, battery technology, healthcare diagnostics, and real estate all catching analyst skepticism.

Here's what changed and where these stocks stood heading into the week:

Biotech Takes a Hit

Andy Chen at Wolfe Research downgraded argenx SE - ADR (ARGX) from Outperform to Peer Perform. That's Wall Street speak for "we no longer think this stock will beat its peers." Argenx closed Friday at $918.92, a hefty price tag that apparently no longer justifies the premium outlook.

Energy and Battery Pullbacks

In the energy space, Keybanc analyst Tim Rezvan moved Kimbell Royalty Partners LP (KRP) from Overweight to Sector Weight. The stock finished Friday at $13.25, now viewed as fairly valued rather than a standout opportunity.

Meanwhile, QuantumScape Corp (QS) got an interesting mixed message from Evercore ISI Group analyst Chris McNally. He downgraded the battery technology company from Outperform to In-Line, but simultaneously raised his price target from $8 to $12. The stock closed Friday at $11.47, suggesting McNally sees some upside but not enough to justify a bullish rating anymore.

Healthcare and Real Estate Caution

Jefferies analyst Brandon Couillard took Exact Sciences Corp (EXAS) from Buy to Hold, though he boosted his price target from $90 to $105. With the stock closing at $100.90 on Friday, that's a classic case of "we like it, but not here"—acknowledging value while suggesting limited near-term upside.

Rounding out Monday's downgrades, JP Morgan analyst Anthony Paolone dropped Brandywine Realty Trust (BDN) from Neutral to Underweight. The real estate trust closed at $3.46 on Friday, and Paolone apparently sees more downside ahead for the office property owner.

The common thread? Analysts reassessing risk-reward ratios as stocks approach or exceed price targets, or fundamentals shift enough to warrant caution. These moves don't necessarily mean sell immediately, but they do signal that the easy money—if there was any—may have already been made.

Back to News

Analyst Loses Faith in Argenx: 5 Notable Downgrades to Start the Week

MarketDash Editorial Team
14 days ago
Wall Street analysts pulled back their bullish stances on several stocks Monday, with Argenx taking the biggest hit as Wolfe Research shifted from Outperform to Peer Perform. Other downgrades hit energy, battery tech, healthcare, and real estate sectors.

Some Wall Street analysts are having second thoughts. Monday brought a wave of downgrades across sectors, with biotechnology, energy partnerships, battery technology, healthcare diagnostics, and real estate all catching analyst skepticism.

Here's what changed and where these stocks stood heading into the week:

Biotech Takes a Hit

Andy Chen at Wolfe Research downgraded argenx SE - ADR (ARGX) from Outperform to Peer Perform. That's Wall Street speak for "we no longer think this stock will beat its peers." Argenx closed Friday at $918.92, a hefty price tag that apparently no longer justifies the premium outlook.

Energy and Battery Pullbacks

In the energy space, Keybanc analyst Tim Rezvan moved Kimbell Royalty Partners LP (KRP) from Overweight to Sector Weight. The stock finished Friday at $13.25, now viewed as fairly valued rather than a standout opportunity.

Meanwhile, QuantumScape Corp (QS) got an interesting mixed message from Evercore ISI Group analyst Chris McNally. He downgraded the battery technology company from Outperform to In-Line, but simultaneously raised his price target from $8 to $12. The stock closed Friday at $11.47, suggesting McNally sees some upside but not enough to justify a bullish rating anymore.

Healthcare and Real Estate Caution

Jefferies analyst Brandon Couillard took Exact Sciences Corp (EXAS) from Buy to Hold, though he boosted his price target from $90 to $105. With the stock closing at $100.90 on Friday, that's a classic case of "we like it, but not here"—acknowledging value while suggesting limited near-term upside.

Rounding out Monday's downgrades, JP Morgan analyst Anthony Paolone dropped Brandywine Realty Trust (BDN) from Neutral to Underweight. The real estate trust closed at $3.46 on Friday, and Paolone apparently sees more downside ahead for the office property owner.

The common thread? Analysts reassessing risk-reward ratios as stocks approach or exceed price targets, or fundamentals shift enough to warrant caution. These moves don't necessarily mean sell immediately, but they do signal that the easy money—if there was any—may have already been made.

    Analyst Loses Faith in Argenx: 5 Notable Downgrades to Start the Week - MarketDash News